Kevin M Nash, Brian A Boe, Sergio A Carrillo, Andrew Harrison, Ryuma Iwaki, John Kelly, Robert D Kirkton, Ramkumar Krishnamurthy, Jeffrey H Lawson, Yuichi Matsuzaki, Heather L Prichard, Kejal Shah, Toshiharu Shinoka, Christopher K Breuer
OBJECTIVES: Palliative treatment of cyanotic congenital heart disease (CCHD) uses systemic-to-pulmonary conduits, often a modified Blalock-Taussig-Thomas shunt (mBTTs). Expanded polytetrafluoroethylene (ePTFE) mBTTs have associated risks for thrombosis and infection. The Human Acellular Vessel (HAV) (Humacyte, Inc) is a decellularized tissue-engineered blood vessel currently in clinical trials in adults for vascular trauma, peripheral artery disease, and end-stage renal disease requiring hemodialysis...
September 2023: JTCVS open